FAST-funded research is giving clinical trials a better way to capture how individuals living with Angelman syndrome communicate in everyday life.
Research led by Bryce Reeve, PhD, and the Center for Health Measurement at Duke University
Quick Summary
FAST-funded work led by Dr. Bryce Reeve and the Duke University team has developed and tested the Observer-Reported Communication Ability (ORCA) measure, a caregiver-completed tool designed to capture communication changes in everyday life.
What researchers learned: The team tested ORCA with nearly 300 caregivers and found that it reliably captures a broad range of communication abilities and aligns well with other communication measures.
What is new: Researchers now have clearer guidance on how to interpret ORCA scores, including that a change of about 2 T-score points can be considered meaningful for individuals living with Angelman syndrome.
Why it matters: Communication is one of the areas families most want new treatments to improve. ORCA gives clinical trials a way to measure those changes using what caregivers observe in everyday life. ORCA is already being used in Angelman syndrome clinical trials and natural history studies and is being prepared for wider use in over a dozen other neurodevelopmental genetic conditions.
About the Study
When FAST first partnered with Dr. Bryce Reeve and the Duke team in 2018, the goal was to develop a communication measure that better reflected what families see in everyday life. The team also wanted a measure that could detect changes in communication during a clinical trial.
To ground ORCA in family experience, researchers began by interviewing communication experts and caregivers of individuals living with Angelman syndrome. Caregivers described the different ways their loved ones communicate, including eye gaze, reaching, vocalizations, and use of augmentative and alternative communication, or AAC devices. The interviews helped shape the framework for ORCA and its three main areas of communication: expressive, receptive, and pragmatic communication.
The team then refined the questionnaire with caregiver feedback and tested it with about 295 caregivers. Researchers looked at whether ORCA scores were reliable, aligned with other communication measures, and could capture a broad range of communication abilities. The results showed strong reliability and alignment with other communication measures.
More recently, the team developed additional scoring approaches, including separate scores for expressive, receptive, pragmatic, and overall communication, and established guidance for how much of a change in ORCA score may be meaningful. A change of about 2 T-score points can be considered a meaningful difference for individuals living with Angelman syndrome.
FAQ for Families
What does a meaningful change in ORCA score actually mean? ORCA scores are reported as T-scores. Based on the team’s research, a change of approximately 2 points can represent a meaningful difference in communication abilities for individuals living with Angelman syndrome, based on caregiver reports.
That does not mean every individual will show the same kind of change. ORCA is designed to capture communication across a wide range of abilities, so meaningful progress may look different from person to person.
Is ORCA already being used in clinical trials and studies? Yes. ORCA has been included in Angelman syndrome clinical trials sponsored by companies such as Neuren, Roche, Ionis, MavriX Bio, and Ultragenyx, and several natural history studies around the world. Its use across multiple studies means researchers are already applying the measure in real-world drug development settings.
What does this mean for my loved one living with Angelman syndrome today? ORCA does not change day-to-day medical care on its own. Its value is in helping researchers better measure whether an investigational treatment is impacting communication abilities in a meaningful way in every day life.
As more Angelman syndrome programs move through clinical development, having better ways to measure communication will be an important part of understanding what those treatments are actually doing.
How This Fits FAST’s Funding Strategy
This work falls under Pillar 5: Clinical Trial Readiness, which focuses on building the tools, data, and infrastructure needed to design strong clinical trials and evaluate potential treatments.
Developing a therapy is only one part of drug development. Researchers also need reliable ways to measure whether a treatment is having an effect and whether that change is meaningful for individuals living with Angelman syndrome.
ORCA gives researchers a way to measure communication changes across a wide range of abilities, including expressive, receptive, and pragmatic communication, to reflect what caregivers observe in everyday life.
FAST support also helped move ORCA from a research tool toward broader use in clinical studies, including automated scoring, guidance for researchers, translations, and integration with Pattern Health’s digital platform.
The success of the FAST-funded ORCA work also led to a five-year grant from the FDA through its Patient-Focused Drug Development initiative, supporting the expansion of ORCA into more than a dozen other rare neurodevelopmental disorders.
Support Clinical Trial Readiness
Work like ORCA shows why clinical trial readiness matters. Researchers need strong measures to understand whether potential treatments are having an effect and whether those changes matter in everyday life.
Your support helps FAST continue funding the research and tools needed to move Angelman syndrome treatment development forward.